NeuroSense Therapeutics Ltd. Warrant (NRSNW) EPS by Year
NRSNWNASDAQ
NeuroSense Therapeutics Ltd. Warrant lost $0.44 per diluted share in fiscal year 2025. The change from the prior fiscal year is not meaningful, because that figure was zero or negative. The table below carries 5 fiscal years, from 2021 to 2025, and the quarters NeuroSense Therapeutics Ltd. Warrant has filed alongside them.
FY2025 annual
EPS (Diluted)-$0.44
YoYn/m
Source SEC Filings (20-F/6-K)Latest period FY2025, ended Dec 31, 2025ReportedCurrency USD
Annual figures, oldest first. Point at a bar to read its period.
NRSNW EPS (Diluted) by Fiscal Year
Figures are as reported in USD. Each change compares the year with the year before it, and each column links to the filing it was taken from.
Diluted earnings per share divides net income by the share count the company would have if every option and convertible security were exercised, which is the more conservative of the two per-share figures a filer reports.
More NeuroSense Therapeutics Ltd. Warrant financials
What was NeuroSense Therapeutics Ltd. Warrant's diluted earnings per share in fiscal year 2025?
NeuroSense Therapeutics Ltd. Warrant lost $0.44 per diluted share in fiscal year 2025.
How fast is NeuroSense Therapeutics Ltd. Warrant's diluted earnings per share growing?
NeuroSense Therapeutics Ltd. Warrant (NRSNW) reported a loss of $0.54 per diluted share in fiscal year 2024 and a loss of $0.44 per diluted share in fiscal year 2025. A growth rate is not meaningful here, because the earlier figure was zero or negative.
How has NeuroSense Therapeutics Ltd. Warrant's diluted earnings per share changed over the years?
Across the 5 fiscal years this page covers, NeuroSense Therapeutics Ltd. Warrant (NRSNW) diluted earnings per share went from -$0.52 in fiscal year 2021 to -$0.44 in fiscal year 2025.
What does diluted earnings per share mean on a financial statement?
Diluted earnings per share divides net income by the share count the company would have if every option and convertible security were exercised, which is the more conservative of the two per-share figures a filer reports. This page lists what NeuroSense Therapeutics Ltd. Warrant (NRSNW) reported on that line in every period on record.
